Pharmacokinetics of flunixin meglumine in mature swine after intravenous, intramuscular and oral administration.

Citation data:

BMC veterinary research, ISSN: 1746-6148, Vol: 9, Issue: 1, Page: 165

Publication Year:
2013
Usage 429
Abstract Views 226
Full Text Views 122
Downloads 81
Captures 8
Exports-Saves 8
Citations 11
Citation Indexes 11
Repository URL:
https://lib.dr.iastate.edu/ans_pubs/95; https://works.bepress.com/anna_butters-johnson/50; https://works.bepress.com/kenneth_stalder/153
PMID:
23941181
DOI:
10.1186/1746-6148-9-165
PMCID:
PMC3751365
Author(s):
Pairis-Garcia, Monique D.; Karriker, Locke A.; Johnson, Anna K.; Kukanich, Butch; Wulf, Larry W.; Sander, Suzanne Mary; Millman, Suzanne T.; Stalder, Kenneth J; Coetzee, Johann F.
Publisher(s):
Springer Nature
Tags:
Veterinary; Swine; gilt; lameness; funixin meglumine; pharmacokinetics; NSAIDs; oral bioavailability
article description
The purpose of this study was to determine intravenous (IV), intramuscular (IM) and oral (PO) FM PK in mature swine. Appropriate pain management for lameness in swine is a critical control point for veterinarians and producers, but science-based guidance on optimal housing, management and treatment of lameness is deficient. Six mature swine (121-168 kg) were administered an IV, IM, or PO dose of flunixin meglumine at a target dose of 2.2 mg/kg in a cross-over design with a 10 day washout period between treatments. Plasma samples collected up to 48 hours post-administration were analyzed by high pressure liquid chromatography and mass spectrometry (HPLC-MS) followed by non-compartmental pharmacokinetic analysis.